Syndax Pharmaceuticals (SNDX) H.C. Wainwright 27th Annual Global Investment Conference summary
Event summary combining transcript, slides, and related documents.
H.C. Wainwright 27th Annual Global Investment Conference summary
9 Jul, 2026Business highlights and financial performance
Achieved $100 million in net sales in the first six months, exceeding expectations and supporting a path to profitability.
Maintains over $500 million in cash with a stabilizing expense base, enabling investment in multi-billion dollar franchises.
Both products, Revuforj and Niktimvo, are contributing significantly to cash flow and profitability.
Early launches of both products have been highly successful, with strong momentum projected into 2025 and beyond.
Revuforj: Market position and growth
First and only FDA-approved menin inhibitor for relapsed/refractory acute leukemia with KMT2A translocation, approved in late 2024.
Achieved 43% quarter-over-quarter sales growth, with $28.6 million in Q2 and over 1,300 prescriptions since launch.
Penetration expected to reach 50% of the 2,000-patient incidence population by year-end.
Anticipates first approval for relapsed/refractory NPM1 in October, expanding the addressable market to 6,500 patients.
Robust development strategy targets both relapsed/refractory and frontline disease, aiming for a $5 billion total addressable market.
Niktimvo: Launch and market expansion
First and only FDA-approved CSF1R antibody for chronic GVHD, launched in early 2024.
Achieved profitability in the first full quarter, with $36.2 million in net sales and $9.4 million in collaboration revenue.
Over 700 patients treated and more than 4,000 infusions administered, with 80%-90% patient persistence.
Targeting a $2 billion market in third line plus, with plans to expand into earlier lines and IPF, potentially unlocking a $5 billion market.
Co-commercialization with Incyte provides commercial synergies and broad market reach.
Latest events from Syndax Pharmaceuticals
- Maintenance growth and frontline trials support a new phase of pipeline expansion.SNDX
Stifel 2026 Healthcare Conference 2026 - Earlier-line trials and maintenance dynamics are central to franchise expansion.SNDX
3rd Annual Guggenheim Healthcare Innovation Conference - Revenue rose 82% as Revuforj and Niktimvo grew and clinical programs advanced.SNDX
Q3 2026 - Strong commercial growth and pivotal trial catalysts highlight a transformative year ahead.SNDX
H.C. Wainwright 28th Annual Global Investment Conference - Dominant AML market share, advancing pivotal trials, and expanding pipeline in oncology and fibrosis.SNDX
Citigroup’s Biopharma Back to School Summit 2026 - Q2 2026 revenue surged 92% YoY, driven by Revuforj and Niktimvo growth and pipeline progress.SNDX
Q2 2026 - Expanding pipeline and late-stage programs drive growth and value across major indications.SNDX
R&D Day 2026 - Two product launches target multi-billion dollar markets with robust early adoption and expansion plans.SNDX
TD Cowen 45th Annual Healthcare Conference - FDA approves Niktimvo for refractory chronic GVHD, with U.S. launch expected by early Q1 2025.SNDX
FDA Announcement